首页 > 市场调查报告书 > 製药

疫苗癌症

市场调查报告书

商品编码

1842724

DNA癌症疫苗的全球市场:临床试验，开发技术平台，市场机会预测(2026年)

Global DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026

出版日期: 2025年10月01日 | 出版商:

KuicK Research | 英文 130 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球DNA癌症疫苗市场：临床试验、技术平台开发及市场机会展望（2026）报告的主要发现与亮点

首个DNA癌症疫苗预计将于2030年获得商业批准
正在进行临床试验的DNA癌症疫苗：超过20种疫苗
全球DNA癌症疫苗临床试验洞察：按公司、适应症和阶段划分
DNA癌症疫苗开发技术平台洞察：超过10个平台
与其他癌症免疫疗法的比较
DNA癌症疫苗的最新创新
竞争格局

癌症DNA疫苗的需求及本报告的意义

癌症持续存在…癌症在全球范围内造成了毁灭性的影响，新增病例数百万，死亡率居高不下，尤其对于晚期和难治性癌症而言更是如此。虽然免疫疗法（例如免疫检查点抑制剂）彻底改变了癌症治疗格局，但它们并非完全有效。 DNA疫苗透过递送编码在质粒DNA中的肿瘤特异性抗原，活化人体的免疫反应来识别和靶向癌细胞，标誌着癌症治疗进入了一个新时代。 DNA疫苗因其安全性、稳定性、快速生产和个人化/可调控性而备受青睐。

这份及时且亟需的报告为从研究人员到投资者的利害关係人提供了关于当前癌症DNA疫苗研发状况的清晰见解。它总结了现有的临床活动、新兴技术、关键公司和策略合作伙伴关係。随着该领域的快速发展，这份报告以清晰易懂的方式呈现了创新的发展方向、重要性以及它将如何改变癌症治疗的未来。

本报告涵盖的癌症DNA疫苗临床试验概况

DNA疫苗目前正处于临床开发阶段，许多疫苗已进入中后期开发阶段。其中，Inovio Pharmaceuticals公司针对HPV相关子宫颈癌的候选疫苗是目前最先进的候选疫苗之一，该疫苗采用电穿孔技术递送质粒DNA，展示了DNA疫苗如何用于抗病毒驱动的癌症。 Imunon公司的IMNN-001目前正在进行卵巢癌的临床试验，该疫苗将DNA与IL-12免疫刺激疗法和化疗相结合，并在II期临床试验中显示出令人鼓舞的生存趋势。

本概述重点介绍了黑色素瘤、肺癌和前列腺癌的全球临床试验，深入分析了临床试验阶段、递送策略、联合用药方案和免疫学终点。所提供的数据有助于了解哪些策略最接近临床应用，以及未来的研究方向。

技术平台、合作关係与协定

平台和递送技术的进步是DNA疫苗技术的基石。虽然电穿孔仍然是提高疫苗吸收率的主要方法，但其他系统正在迅速发展。例如，NEC生物治疗公司正在测试一种口服DNA疫苗，该疫苗利用机器学习来识别和针对患者特异性的肿瘤突变。 Imunon公司的PlaCCine®平台最初是为传染病设计的，但由于其能够以更高的稳定性递送多种抗原，因此正在被重新用于肿瘤治疗。

本报告概述了重要的合作项目，包括Immunocure与PharmaJet的合作，后者采用无针皮内注射系统来提高患者依从性和免疫反应。这些合作是将专有DNA构建体与第三方递送系统结合以加快开发和规模化生产的更大趋势的一部分。

癌症DNA疫苗研发领域的主要公司

许多公司处于该领域的前沿。 Inovio、Scancell、Imunon和NEC Bio都在研发和临床试验方面投入了大量资源。 Scancell的皮内注射iSCIB1+黑色素瘤疫苗与免疫检查点抑制剂合併使用，目前正在透过英国国家医疗服务体系（NHS）癌症疫苗启动平台招募病患。本报告对这些公司及其他公司进行了介绍，概述了它们的研发管线、感兴趣的治疗领域、递送机制和策略合作伙伴关係。

报告展望癌症DNA疫苗的未来发展方向

本报告指出，癌症DNA疫苗领域存在着推动下一代创新发展的巨大机遇，包括应用微环DNA（mcDNA）实现更清洁、更高效的基因表达；开发基于DNA摺纸技术的平台（如DoriVac）进行靶向免疫刺激；以及利用基因编辑工具（包括CRISPR）优化疫苗构建体。

此外，诸如 LungVax（一种目前正在英国研发的针对肺癌高危险群的 DNA 疫苗）等预防性方法表明，DNA 疫苗的应用范围将超越治疗范畴。

随着临床证据的累积、递送装置的改进以及与现有疗法相容性的提高，DNA 癌症疫苗有望在未来几年成为癌症治疗的核心支柱。

First DNA Cancer Vaccine commercial Approval Expected By 2030
DNA Cancer Vaccines In Clinical Trials: > 20 Vaccines
Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase
Insight On DNA Cancer Vaccine Development Technology Platforms: >10 Platforms
Comparison With Other Cancer Immunotherapies
DNA Cancer Vaccines Recent Innovations
Competitive Landscape

Need For Cancer DNA Vaccines and Why This Report

The global impact of cancer remains profound, with millions of new cases and high mortality, particularly in advanced and hard to treat cancers. Although immunotherapies such as checkpoint inhibitors have transformed the cancer therapeutic landscape, they are not effective across the board. DNA vaccines present a new era of cancer therapy by providing tumor specific antigens encoded in plasmid DNA that activate the body's immune response to detect and target cancer cells. They are attractive due to their safety, stability, fast production, and the ability to be tailored or personalized.

This report is timely and much needed, providing stakeholders, ranging from researchers to investors, clear insight into the current state of cancer DNA vaccine development. It summarizes the existing clinical activity, nascent technologies, key companies, and strategic partnerships. As the field rapidly advances, the report delivers a well-curated, recent snapshot of where innovation is headed, why it is important, and how it might transform the future of cancer care.

Cancer DNA Vaccines Clinical Trials Insight Covered In Report

DNA vaccines are currently in clinical development, many of them moving into mid to late stage testing. One of the most advanced, Inovio Pharmaceuticals' HPV-associated cervical cancer candidate based on plasmid DNA administered using electroporation, shows how DNA vaccines can be used against virus-driven cancers. IMUNON's IMNN-001, being tested for ovarian cancer, combines DNA with IL-12 immunostimulation and chemotherapy and is reporting promising survival trends in Phase II.

This overview calls attention to the scale of global clinical trials, such as melanoma, lung, and prostate cancer, and offers insights into trial phases, delivery strategies, combination regimens, and immunological endpoints. Data provided serves to place into context which strategies are most proximal to clinical translation and how future efforts will look like.

Technology Platforms, Partnerships & Agreements

Platform and delivery advancements are the cornerstone of DNA vaccine technology. Electroporation is still a dominant way to deliver improved uptake, but other systems are picking up steam. NEC Bio Therapeutics, for example, is testing an oral, bacteria-delivery based DNA vaccine that uses machine learning to identify patient-specific tumor mutations for targeting. IMUNON's PlaCCine(R) platform, initially designed for infectious disease, is being repurposed for oncology because it has the ability to deliver multiple antigens with improved stability.

The report outlines major collaborations, including Immuno Cure and PharmaJet's partnership, which employs a needle-free intradermal injection system to enhance patient compliance and immune response. These collaborations are part of a larger trend of merging proprietary DNA constructs with third-party delivery systems for faster development and scale-up.

Leading Companies Active In RandD On Cancer DNA Vaccines

A number of companies are at the forefront in this field. Inovio, Scancell, IMUNON, and NEC Bio are all committing significant resources to R&D and clinical trials. Scancell's intradermally delivered iSCIB1+ melanoma vaccine, administered in combination with checkpoint inhibitors, is recruiting patients on the UK's NHS Cancer Vaccine Launch Pad. The report outlines these companies and others, providing an overview of their pipelines, therapeutic areas of interest, delivery mechanisms, and strategic partnerships.

Report Indicating Future Development Of Cancer DNA Vaccines

Looking ahead, the report points out significant opportunities fueling the next generation of innovation. These are the application of minicircle DNA (mcDNA) for cleaner, more efficient gene expression, the development of DNA origami-based platforms such as DoriVac for targeted immune stimulation, and gene editing tools including CRISPR to optimize vaccine constructs. Furthermore, preventive approaches such as LungVax, a DNA vaccine in development in the UK for patients at high risk of lung cancer, point to an even wider use of DNA vaccines beyond therapy.

As more clinical evidence mounts, improved delivery devices, and compatibility with current therapies, DNA cancer vaccines will be a central column of oncology treatment in the years to come.

1. Overview Of DNA Cancer Vaccines

1.1 What Are DNA Cancer Vaccines?
1.2 History & Development Timeline
1.3 Comparison With Other Cancer Immunotherapies
1.4 Advantages & Limitations

2. DNA Cancer Vaccines - Mechanism of Action

2.1 How DNA Vaccines Work
2.2 Antigen Selection & Delivery
2.3 Role Of Vectors & Adjuvants
2.4 Immune Activation Pathways

3. Global DNA Cancer Vaccines - Recent Innovations

4. Global DNA Cancer Vaccines Market Overview

4.1 Current Market Scenario
4.2 Future Opportunity Outlook

5. DNA Cancer Vaccine Development Trends By Indication

5.1 Prostate Cancer
5.2 Cervical Cancer
5.3 Lung Cancer
5.4 Melanoma
5.5 Breast Cancer

6. DNA Cancer Vaccine Development Technology Platforms

7. Global DNA Cancer Vaccines Clinical Trials Overview

7.1 By Company
7.2 By Indication
7.3 By Phase

8. Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase

8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II
8.5 Phase III

9. Global DNA Cancer Vaccines Market Dynamics

9.1 Growth Drivers & Opportunities
9.2 Market Restraints & Solutions

10. Competitive Landscape

10.1 4basebio
10.2 Aston Sci
10.3 Genexine
10.4 Evaxion
10.5 Immunomic Therapeutics
10.6 INOVIO
10.7 Madison Vaccines
10.8 Nykode Therapeutics
10.9 PapiVax Biotech
10.10 Takis

简介目录图表

List of Figures

Figure 1-1: DNA Cancer Vaccines - Mechanism
Figure 1-2: DNA Cancer Vaccine - Milestones
Figure 1-3: DNA Cancer Vaccines - Safety Profile
Figure 1-4: DNA Vaccines vs. Other Immunotherapies - Durability Of Response
Figure 1-5: DNA Vaccine Delivery Methods
Figure 1-6: DNA Vaccine Immunogenicity - Challenges
Figure 2-1: DNA Vaccine Immune Response
Figure 2-2: DNA Vaccine - Antigen Presentation To Immune System
Figure 2-3: DNA Cancer Vaccine - Final Immune Response
Figure 2-4: Types Of Tumor Antigens
Figure 2-5: Challenges with Antigen Selection
Figure 2-6: Plasmid Vectors
Figure 2-7: Bacterial Vectors
Figure 2-8: Viral Vectors
Figure 2-9: Adjuvants In DNA Cancer Vaccines
Figure 2-10: New Developments In Adjuvants
Figure 2-11: DNA Sensors & Their Roles in Immune Activation
Figure 3-1: DoriVac DNA Vaccine Mechanism
Figure 3-2: μEPO System - Key Features & Breakthroughs
Figure 3-3: Neomatrix Biotech: Revolutionizing Personalized Cancer Immunotherapy
Figure 4-1: Global DNA Cancer Vaccines Market - Future Opportunities
Figure 5-1: UW18037 Phase 2 (NCT04090528) Study - Initiation & Completion Year
Figure 5-2: UW25025 Phase 1 (NCT07090148) Study - Initiation & Completion Year
Figure 5-3: UW18008 Phase 2 (NCT03600350) Study - Initiation & Completion Year
Figure 5-4: J23105sIRB Phase 1 (NCT06315257) Study - Initiation & Completion Year
Figure 5-5: J1955 Phase 2 (NCT04131413) Study - Initiation & Completion Year
Figure 5-6: BB IND 18340 Phase 1 (NCT03913117) Study - Initiation & Completion Year
Figure 5-7: NEWISH-HPV-101 Phase 1 (NCT06276101) Study - Initiation & Completion Year
Figure 5-8: 202104143 Phase 2 (NCT04397003) Study - Initiation & Completion Year
Figure 5-9: NCI-2021-14159 Phase 2 (NCT05242965) Study - Initiation & Completion Year
Figure 5-10: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-11: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-12: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-13: W81XWH-15-1-0101 Phase 1 (NCT02204098) Study - Initiation & Completion Year
Figure 5-14: NCI-2014-01070 Phase 1 (NCT02157051) Study - Initiation & Completion Year
Figure 5-15: NCI-2025-04692 Phase 2 (NCT07112053) Study - Initiation & Completion Year
Figure 5-16: NCI-2020-01662 Phase 2 (NCT04329065) Study - Initiation & Completion Year
Figure 5-17: NECVAX-NEO1-05-DE Phase 1/2 (NCT06631092) Study - Initiation & Completion Year
Figure 6-1: Enzymatic manufacturing process
Figure 6-2: Genexine - DNA Vaccine Platform
Figure 6-3: MVI Technology - DNA Plasmid Mechanism Of Action
Figure 6-4: Nykode - Protein Format
Figure 6-5: Nykode Therapeutics - DNA Vaccine Mechanism Of Action
Figure 6-6: DNA Medicines Technology - INOVIO
Figure 6-7: UNITE - Mode Of Action
Figure 6-8: GT-EPIC Platform - Process
Figure 6-9: LineaDNA - Production Process
Figure 6-10: GeneOne DNA Plasmid Technology - Principle
Figure 6-11: Fusogenix - FAST Protein Structure
Figure 6-12: PLV Technology
Figure 6-13: PLV Technology - Delivery Mechanism
Figure 7-1: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Company , 2025 -2026
Figure 7-2: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2025 -2026
Figure 7-3: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2025 - 2026
Figure 9-1: Global DNA Cancer Vaccines Market - Drivers & Opportunities
Figure 9-2: Global DNA Cancer Vaccines Market - Restraints & Solutions

List of Tables

Table 1-1: DNA Cancer Vaccines - Delivery Methods
Table 1-2: DNA Vaccine Platforms - Comparison
Table 1-3: DNA Cancer Vaccines - Comparison With Other Immunotherapies
Table 1-4: DNA Cancer Vaccines vs. mRNA Vaccines
Table 1-5: DNA Cancer Vaccines - Scalability & Manufacturing
Table 1-6: DNA Cancer Vaccines - Advantages
Table 6-1: LineaDNA - At A Glace

02-2729-4219

+886-2-2729-4219

License/价格

DNA癌症疫苗的全球市场:临床试验，开发技术平台，市场机会预测(2026年)

Global DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026

目录

第1章 DNA癌症疫苗概要

第2章 DNA癌症疫苗- 作用机制

第3章全球的DNA癌症疫苗- 最近的革新

第4章全球DNA癌症疫苗市场概要

第5章各适应症的DNA癌症疫苗开发趋势

第6章 DNA癌症疫苗开发技术平台

第7章全球的DNA癌症疫苗临床试验概要

第8章企业，适应症，各期的全球的DNA癌症疫苗临床试验的洞察

第9章全球DNA癌症疫苗市场动态

第10章竞争情形